FKBP1B

Peptidyl-prolyl cis-trans isomerase FKBP1B · P68106 · FKBP1B on Sugi Atlas →

7,199 patent compounds predicted against FKBP1B, 5,551 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Cyclosporine (SCHEMBL1653705)	0.87	3/20
Cyclosporine (SCHEMBL1653706)	0.87	3/20
Cyclosporine (SCHEMBL7886918)	0.86	3/20
Cyclosporine (SCHEMBL4533831)	0.84	3/20
Cyclosporine (SCHEMBL4533834)	0.84	3/20
Cyclosporine (SCHEMBL7622649)	0.81	3/20
Cyclosporine (SCHEMBL6241205)	0.78	3/20
Cyclosporine (SCHEMBL3134548)	0.75	3/20
Cyclosporine (SCHEMBL3005047)	0.74	3/20
Cyclosporine (SCHEMBL296158)	0.70	3/20
Cyclosporine (SCHEMBL6936200)	0.70	3/20
Cyclosporine (SCHEMBL3668874)	0.69	3/20
Cyclosporine (SCHEMBL8437574)	0.69	3/20
Cyclosporine (SCHEMBL1461528)	0.68	3/20
SCHEMBL3746035	0.65	3/20
Cyclosporine (SCHEMBL6442662)	0.64	3/20
Cyclosporine (SCHEMBL2009060)	0.62	3/20
Cyclosporine (SCHEMBL5663144)	0.59	3/20
Cyclosporine (SCHEMBL7515620)	0.56	3/20
Cyclosporine (SCHEMBL8034888)	0.56	3/20

Clinical trials — most relevant to FKBP1B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Topical Metformin Emulgel VS Salicylic Acid Peeling in Treatment of Acne Vulgaris	PHASE4	UNKNOWN
A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I Disorder	PHASE3	COMPLETED
A Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-release Paliperidone in Subjects With Bipolar I Disorder	PHASE3	COMPLETED
Rapamycin for Immunosuppression and B Cell Modulation Post Stem Cell Transplant for Acute Lymphoblastic Leukemia (ALL)	PHASE2	COMPLETED
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer	PHASE2	COMPLETED
Neurosteroids for PTSD in Veterans	PHASE2	COMPLETED
Targeting Endoplasmic Reticulum Stress in Human Hypertension	PHASE1/PHASE2	RECRUITING
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors	PHASE1	WITHDRAWN
Multimodal Neuroimaging of Alcohol Cues, Cortisol Response, and Compulsive Motivation	EARLY_PHASE1	COMPLETED
FKBP5 Methylation and Childhood Emotional Abuse in Complex Posttraumatic Stress Disorder: Investigating the Relationship and Its Predictive Role in Therapy Outcome	nan	COMPLETED
Clinical Implications of FKBP5 in Stroke	nan	UNKNOWN
Cortisol, Hippocampus, and Insula in Anorexia Nervosa.	nan	RECRUITING
Quantification of GADD34 Expression in RA	nan	COMPLETED
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA	nan	RECRUITING
Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer	nan	WITHDRAWN
Gene Polymorphisms in Tacrolimus Drug Interactions	nan	COMPLETED
A Study on Psychopathological Progress of Early Schizophrenia-Like Disorder (SOPRES)	nan	UNKNOWN
Genetic Predictors of Lithium Response in Bipolar Disorder	nan	COMPLETED
Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia	nan	COMPLETED
Post-Deployment Afghanistan/Iraq Trauma Related Inventory of Traits (PATRIOT): Phase 1 (Feasibility Study)	nan	COMPLETED
Breathing Focused Yoga in Social Anxiety Disorder	nan	COMPLETED
Multi-level Molecular Profiling of High Acute Stress: a Clinical Study	nan	UNKNOWN
Genomics of Posttraumatic Stress Disorder in Veterans	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)	nan	RECRUITING
Fibromyalgia Different Approaches: Acupuncture vs Migratens	nan	UNKNOWN
Memory and the Hippocampus in Twins	nan	COMPLETED
PROspective Longitudinal All-comer Inclusion Study in Eating Disorders	nan	RECRUITING
PhaRmacOgenetics and Therapeutic Drug Monitoring In SchizophrEnia	nan	NOT_YET_RECRUITING
Identifying New Therapeutic Targets for Lupus Treatment	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a FKBP1B binder may also engage these)

Protein	Name	Similarity
P68107	—	1.000	P68107 →
P97534	—	1.000	P97534 →
Q9Z2I2	—	1.000	Q9Z2I2 →
Q8HYX6	—	1.000	Q8HYX6 →
P18203	—	1.000	P18203 →
O42123	—	1.000	O42123 →
P62943	—	1.000	P62943 →
Q62658	—	1.000	Q62658 →
P48375	—	1.000	P48375 →
Q5VVH2	—	0.999	Q5VVH2 →
O42993	—	0.997	O42993 →
Q6KBA8	—	0.997	Q6KBA8 →
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	0.996	landscape →
Q6BX45	—	0.994	Q6BX45 →
Q6CF41	—	0.993	Q6CF41 →
Q754K8	—	0.993	Q754K8 →
Q6CX30	—	0.993	Q6CX30 →
P26883	—	0.993	P26883 →
P20080	—	0.993	P20080 →
P20081	—	0.992	P20081 →
O94746	—	0.992	O94746 →
P0CP95	—	0.989	P0CP95 →
Q6M981	—	0.989	Q6M981 →
Q6FMA3	—	0.989	Q6FMA3 →
P0C1J3	—	0.989	P0C1J3 →
P0CP94	—	0.988	P0CP94 →
Q4HZB8	—	0.987	Q4HZB8 →
Q4WLV6	—	0.987	Q4WLV6 →
P0A0W2	—	0.986	P0A0W2 →
Q4W9R2	—	0.985	Q4W9R2 →